Compare Stocks

Date Range: 

 Constellation PharmaceuticalsZogenixTrillium TherapeuticsG1 TherapeuticsSyndax Pharmaceuticals
SymbolNASDAQ:CNSTNASDAQ:ZGNXNASDAQ:TRILNASDAQ:GTHXNASDAQ:SNDX
Price Information
Current Price$20.80$18.87$9.59$20.60$16.04
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.21.71.71.51.8
Analysis Score3.43.43.53.53.4
Community Score2.42.82.92.42.5
Dividend Score0.00.00.00.00.0
Ownership Score0.01.71.71.72.5
Earnings & Valuation Score0.00.60.60.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$40.33$59.00$21.83$49.17$28.27
% Upside from Price Target93.91% upside212.67% upside127.67% upside138.67% upside76.26% upside
Trade Information
Market Cap$996.61 million$1.05 billion$988.09 million$866.40 million$773.71 million
Beta2.81.62.272.441.8
Average Volume462,367797,0621,441,3251,405,299840,847
Sales & Book Value
Annual RevenueN/A$3.65 million$120,000.00N/A$1.52 million
Price / SalesN/A288.558,234.05N/A509.02
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$8.23 per share$5.54 per share($0.86) per share$6.80 per share$1.16 per share
Price / BookN/A3.41-11.15N/A13.83
Profitability
Net Income$-85,550,000.00$-419,500,000.00$-41,620,000.00$-122,450,000.00$-56,050,000.00
EPS($3.04)($3.90)($1.38)($3.27)($1.84)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-8,758.48%N/AN/A-4,656.63%
Return on Equity (ROE)-28.88%-53.91%-70.00%-49.35%-77.47%
Return on Assets (ROA)-24.98%-36.49%-28.84%-41.53%-52.27%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.05%N/AN/A0.10%0.15%
Current Ratio15.81%4.58%22.44%7.45%11.71%
Quick Ratio15.81%4.58%22.44%7.45%11.71%
Ownership Information
Institutional Ownership PercentageN/A96.57%67.46%77.89%83.78%
Insider Ownership Percentage10.60%3.50%N/A14.49%9.50%
Miscellaneous
Employees154218N/A12243
Shares Outstanding47.91 million55.81 million103.03 million42.06 million48.24 million
Next Earnings Date5/10/2021 (Confirmed)8/4/2021 (Estimated)8/11/2021 (Estimated)8/4/2021 (Estimated)5/11/2021 (Confirmed)
OptionableNot OptionableOptionableOptionableOptionableOptionable
SourceHeadline
DAX Stock News Today – Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) Jumps 4.97%, But Additional Rally May Be Imminent – Marketing SentinelDAX Stock News Today – Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) Jumps 4.97%, But Additional Rally May Be Imminent – Marketing Sentinel
fintechzoom.com - May 8 at 3:00 PM
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) Jumps 4.97%, But Additional Rally May Be ImminentSyndax Pharmaceuticals Inc. (NASDAQ:SNDX) Jumps 4.97%, But Additional Rally May Be Imminent
marketingsentinel.com - May 8 at 9:59 AM
Syndax Pharmaceuticals Inc. (SNDX) has great growth outlook for 2021Syndax Pharmaceuticals Inc. (SNDX) has great growth outlook for 2021
marketingsentinel.com - May 5 at 10:58 AM
Syndax Pharmaceuticals (SNDX) to Release Earnings on TuesdaySyndax Pharmaceuticals (SNDX) to Release Earnings on Tuesday
americanbankingnews.com - May 5 at 10:56 AM
Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021
finance.yahoo.com - May 4 at 7:35 AM
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Recommendation of "Buy" from BrokeragesSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Recommendation of "Buy" from Brokerages
americanbankingnews.com - May 3 at 2:58 AM
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX): Here’s What’s Really Going OnSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX): Here’s What’s Really Going On
stocksregister.com - April 26 at 2:50 PM
Dennis Podlesak Is The Independent Chairman of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) And Just Spent US$197k On SharesDennis Podlesak Is The Independent Chairman of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) And Just Spent US$197k On Shares
finance.yahoo.com - April 25 at 8:57 AM
Syndax Pharmaceuticals Stock Appears To Be Significantly OvervaluedSyndax Pharmaceuticals Stock Appears To Be Significantly Overvalued
uk.finance.yahoo.com - April 24 at 8:04 AM
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 7.1% After Insider Buying ActivitySyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 7.1% After Insider Buying Activity
americanbankingnews.com - April 23 at 10:28 AM
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak Acquires 13,967 SharesSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak Acquires 13,967 Shares
americanbankingnews.com - April 22 at 7:36 PM
Pre-earnings Bullish Momentum Pattern and Trigger in Syndax Pharmaceuticals IncPre-earnings Bullish Momentum Pattern and Trigger in Syndax Pharmaceuticals Inc
cmlviz.com - April 22 at 3:19 PM
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down  Following Analyst DowngradeSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down Following Analyst Downgrade
americanbankingnews.com - April 22 at 10:24 AM
Syndax (SNDX) Moves 10.7% Higher: Will This Strength Last?Syndax (SNDX) Moves 10.7% Higher: Will This Strength Last?
finance.yahoo.com - April 22 at 10:18 AM
Wall Street Analyst Initiated Syndax Pharmaceuticals Inc. [SNDX]. What else is Wall St. sayingWall Street Analyst Initiated Syndax Pharmaceuticals Inc. [SNDX]. What else is Wall St. saying
dbtnews.com - April 21 at 11:34 PM
Syndax Pharmaceuticals (NASDAQ:SNDX) Sees Large Volume IncreaseSyndax Pharmaceuticals (NASDAQ:SNDX) Sees Large Volume Increase
americanbankingnews.com - April 21 at 12:58 PM
46 Biggest Movers From Yesterday46 Biggest Movers From Yesterday
msn.com - April 21 at 8:33 AM
Syndax Pharmaceuticals (NASDAQ:SNDX) PT Lowered to $30.00 at Robert W. BairdSyndax Pharmaceuticals (NASDAQ:SNDX) PT Lowered to $30.00 at Robert W. Baird
americanbankingnews.com - April 21 at 8:28 AM
Syndax Pharmaceuticals (NASDAQ:SNDX) Earns "Buy" Rating from B. RileySyndax Pharmaceuticals (NASDAQ:SNDX) Earns "Buy" Rating from B. Riley
americanbankingnews.com - April 21 at 8:28 AM
Syndax Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:SNDX)Syndax Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:SNDX)
americanbankingnews.com - April 21 at 4:26 AM
Why Syndax Pharmaceuticals Stock Is Sinking TodayWhy Syndax Pharmaceuticals Stock Is Sinking Today
finance.yahoo.com - April 20 at 7:38 PM
31 Stocks Moving In Tuesdays Mid-Day Session31 Stocks Moving In Tuesday's Mid-Day Session
msn.com - April 20 at 2:38 PM
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – Analyst View Looks Different TodaySyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – Analyst View Looks Different Today
marketingsentinel.com - April 20 at 2:38 PM
Syndax Lower as Blood Cancer Drug Trial Disappoints InvestorsSyndax Lower as Blood Cancer Drug Trial Disappoints Investors
finance.yahoo.com - April 20 at 2:38 PM
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Up to $19.38Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Up to $19.38
americanbankingnews.com - April 20 at 11:36 AM
DateCompanyBrokerageAction
4/7/2021Constellation PharmaceuticalsRoyal Bank of CanadaReiterated Rating
1/25/2021Constellation PharmaceuticalsBMO Capital MarketsUpgrade
9/24/2020Constellation PharmaceuticalsOppenheimerReiterated Rating
9/3/2020Constellation PharmaceuticalsBrookline Capital ManagementInitiated Coverage
8/9/2020Constellation PharmaceuticalsJefferies Financial GroupReiterated Rating
8/6/2020Constellation PharmaceuticalsHC WainwrightReiterated Rating
6/24/2020Constellation PharmaceuticalsJMP SecuritiesInitiated Coverage
3/11/2020Constellation PharmaceuticalsRobert W. BairdLower Price Target
3/11/2020Constellation PharmaceuticalsCowenReiterated Rating
2/13/2020Constellation PharmaceuticalsSunTrust BanksInitiated Coverage
12/14/2020ZogenixNeedham & Company LLCReiterated Rating
12/2/2020ZogenixMizuhoReiterated Rating
8/24/2020ZogenixRaymond JamesInitiated Coverage
8/6/2020ZogenixNorthland SecuritiesReiterated Rating
6/26/2020ZogenixWilliam BlairReiterated Rating
5/5/2020ZogenixPiper SandlerLower Price Target
3/5/2020ZogenixCitigroupInitiated Coverage
2/28/2020ZogenixLADENBURG THALM/SH SHReiterated Rating
2/14/2020ZogenixStifel NicolausReiterated Rating
1/21/2020ZogenixGuggenheimReiterated Rating
12/6/2019ZogenixPiper Jaffray CompaniesReiterated Rating
4/29/2021Trillium TherapeuticsBloom BurtonUpgrade
4/26/2021Trillium TherapeuticsJonestradingReiterated Rating
4/20/2021Trillium TherapeuticsBenchmarkInitiated Coverage
11/18/2020Trillium TherapeuticsCraig HallumBoost Price Target
10/12/2020Trillium TherapeuticsEvercore ISIInitiated Coverage
8/20/2020G1 TherapeuticsWedbushReiterated Rating
6/26/2020G1 TherapeuticsRoth CapitalInitiated Coverage
5/12/2020G1 TherapeuticsJPMorgan Chase & Co.Lower Price Target
1/7/2020G1 TherapeuticsBTIG ResearchBoost Price Target
4/21/2021Syndax PharmaceuticalsB. RileyReiterated Rating
12/8/2020Syndax PharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/8/2020Syndax PharmaceuticalsSmith Barney CitigroupBoost Price Target
12/7/2020Syndax PharmaceuticalsMorgan StanleyBoost Price Target
12/7/2020Syndax PharmaceuticalsBarclaysBoost Price Target
5/25/2020Syndax PharmaceuticalsNomuraReiterated Rating
3/26/2020Syndax PharmaceuticalsNomura SecuritiesReiterated Rating
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.